These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 12205502)

  • 21. Divining the path to a successful European exit.
    Buch HK; Gustafsson AC; Drvota V; Sundberg CJ
    Nat Biotechnol; 2011 Mar; 29(3):205-7. PubMed ID: 21510008
    [No Abstract]   [Full Text] [Related]  

  • 22. Biotech's wellspring: the health of private biotech in 2012.
    Huggett B
    Nat Biotechnol; 2013 May; 31(5):396-403. PubMed ID: 23657390
    [No Abstract]   [Full Text] [Related]  

  • 23. Biotech business Down Under.
    Beckley C
    Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
    [No Abstract]   [Full Text] [Related]  

  • 24. Australia: ready for business.
    Woodrow GC; Nisbet I; Corbett ME
    Nat Biotechnol; 1997 Aug; 15(8):731-2. PubMed ID: 9255783
    [No Abstract]   [Full Text] [Related]  

  • 25. Public biotechnology 2002--the numbers.
    Lähteenmäki R; DeFrancesco L
    Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
    [No Abstract]   [Full Text] [Related]  

  • 26. A rollercoaster ride.
    Jacobs T
    Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
    [No Abstract]   [Full Text] [Related]  

  • 27. The Human Genome Project: a public good.
    Hudson K
    Health Matrix Clevel; 2002; 12(2):367-75. PubMed ID: 12430360
    [No Abstract]   [Full Text] [Related]  

  • 28. The perils of subsidiarity.
    Nat Biotechnol; 2004 Dec; 22(12):1483. PubMed ID: 15583638
    [No Abstract]   [Full Text] [Related]  

  • 29. Taiwan: Biotech vision.
    Cyranoski D
    Nat Biotechnol; 2003 Apr; 21(4):463-4. PubMed ID: 12665831
    [No Abstract]   [Full Text] [Related]  

  • 30. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 31. Public biotechnology 2003-the numbers.
    Lähteenmäki R; Baker M
    Nat Biotechnol; 2004 Jun; 22(6):665-70. PubMed ID: 15175683
    [No Abstract]   [Full Text] [Related]  

  • 32. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 33. Marketing biotechnology with a Gallic flair.
    Jouanneau AC
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE36-7. PubMed ID: 12874977
    [No Abstract]   [Full Text] [Related]  

  • 34. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 35. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 36. Europe discovers bioentrepreneurship.
    Haycock P
    Nat Biotechnol; 1998 May; 16 Suppl():6. PubMed ID: 9591249
    [No Abstract]   [Full Text] [Related]  

  • 37. Indian biotechnology--rapidly evolving and industry led.
    Kumar NK; Quach U; Thorsteinsdóttir H; Somsekhar H; Daar AS; Singer PA
    Nat Biotechnol; 2004 Dec; 22 Suppl():DC31-6. PubMed ID: 15583682
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech round the world: focus on Canada.
    Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
    [No Abstract]   [Full Text] [Related]  

  • 39. Public companies get creative in raising finance.
    Hodgson J
    Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161
    [No Abstract]   [Full Text] [Related]  

  • 40. Sustaining agbiotechnology through lean times.
    McElroy D
    Nat Biotechnol; 2003 Sep; 21(9):996-1002. PubMed ID: 12949560
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.